Douglas Ewan Crompton

Douglas Ewan Crompton

Auto-generated profile, based on publicly available information

Douglas Ewan Crompton

Department of Neurology, Northern Health, Epping, VIC, Australia (D.E.C.).

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2013 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
LDLeanne M Dibbens
Leanne M Dibbens
BVBoukje de Vries
Boukje de Vries
SDSimona Donatello
Simona Donatello
SHSarah E Heron
Sarah E Heron
BHBree L Hodgson
Bree L Hodgson
ISIngrid E. Scheffer
Ingrid E. Scheffer

1 December 2016 in Epilepsy Research
Verified
Journal Article
Closed access
MCMonica Cooper
Monica Cooper
AMAnne Mcintosh
Anne Mcintosh
DCDouglas E. Crompton
Douglas E. Crompton
JMJacinta M. McMahon
Jacinta M. McMahon
ASAmy Schneider
Amy Schneider
ISIngrid E. Scheffer
Ingrid E. Scheffer

24 December 2015 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
RBRichard D. Bagnall
Richard D. Bagnall
DCDouglas E. Crompton
Douglas E. Crompton
SPSlavé Petrovski
Slavé Petrovski
LLLien Lam
Lien Lam
CCCarina Cutmore
Carina Cutmore
CSChristopher Semsarian
Christopher Semsarian

1 March 2014 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
ISIngrid E. Scheffer
Ingrid E. Scheffer
SHSarah E. Heron
Sarah E. Heron
BRBrigid M. Regan
Brigid M. Regan
SMSimone Mandelstam
Simone Mandelstam
DCDouglas E. Crompton
Douglas E. Crompton
LDLeanne M Dibbens
Leanne M Dibbens

21 November 2006 in Brain
Verified
Journal Article
Open access
PDF file
PCPatrick F. Chinnery
Patrick F. Chinnery
DCDouglas E. Crompton
Douglas E. Crompton
DBDaniel Birchall
Daniel Birchall
MJMargaret J. Jackson
Margaret J. Jackson
ACAlan Coulthard
Alan Coulthard
John BurnJohn Burn
John Burn
Neuroferritinopathy is a progressive potentially treatable adult-onset movement disorder caused by mutations in the ferritin light chain gene (FTL1). Features overlap with common extrapyramidal disorders: idiopathic torsion dystonia, idiopathic Parkinson's disease and Huntington's disease, but the phenotype and natural history have not been defined. We studied a genetically homogeneous group of 41 subjects with the 460InsA mutation in FTL1, documenting the presentation, clinical course, biochemistry and neuroimaging. The mean age of onset was 39.4 years (SD = 13.3, range 13–63), beginning with chorea in 50%, focal lower limb dystonia in 42.5% and parkinsonism in 7.5%. The majority reported a family history of a movement disorder often misdiagnosed as Huntington's disease. The disease progressed relentlessly, becoming generalized over a 5–10 year period, eventually leading to aphonia, dysphagia and severe motor disability with subcortical/frontal cognitive dysfunction as a late feature. A characteristic action-specific facial dystonia was common (65%), and in 63% there was asymmetry throughout the disease course. Serum ferritin levels were low in the majority of males and post-menopausal females, but within normal limits for pre-menopausal females. MR brain imaging was abnormal on all affected individuals and one presymptomatic carrier. In conclusion, isolated parkinsonism is unusual in neuroferritinopathy, and unlike Huntington's disease, cognitive changes are absent or subtle in the early stages. Depressed serum ferritin is common and provides a useful screening test in routine practice, and gradient echo brain MRI will identify all symptomatic cases.

29 October 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
MCMark Corbett
Mark Corbett
TKThessa Kroes
Thessa Kroes
LVLiana Veneziano
Liana Veneziano
MBMark F. Bennett
Mark F. Bennett
RFRahel Florian
Rahel Florian
JGJozef Gecz
Jozef Gecz
Familial Adult Myoclonic Epilepsy (FAME) is characterised by cortical myoclonic tremor usually from the second decade of life and overt myoclonic or generalised tonic-clonic seizures. Four independent loci have been implicated in FAME on chromosomes (chr) 2, 3, 5 and 8. Using whole genome sequencing and repeat primed PCR, we provide evidence that chr2-linked FAME (FAME2) is caused by an expansion of an ATTTC pentamer within the first intron of STARD7. The ATTTC expansions segregate in 158/158 individuals typically affected by FAME from 22 pedigrees including 16 previously reported families recruited worldwide. RNA sequencing from patient derived fibroblasts shows no accumulation of the AUUUU or AUUUC repeat sequences and STARD7 gene expression is not affected. These data, in combination with other genes bearing similar mutations that have been implicated in FAME, suggest ATTTC expansions may cause this disorder, irrespective of the genomic locus involved.